Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)-Reference-Cited by-同舟云学术

Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)

Published:2023-11-23 Issue:12 Volume:23 Page:1173-1184
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Sekayan Tro¹^ORCID,Simmons Dana H.²^ORCID,von Drygalski Annette¹^ORCID

Affiliation:

1. Division of Hematology/Oncology, Department of Medicine, University of California, San Diego, San Diego, CA, USA

2. Capitol Scientific, Washington DC, USA

Funder

Health Resources and Services Administration

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2023.2282138

Reference66 articles.

1. World Federation of Hemophilia. Report on the annual global survey 2021 [updated Oct 2022; cited 2023 Apr 29]. Available from: https://www1.wfh.org/publications/files/pdf-2324.pdf

2. Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres

3. Definitions in hemophilia: communication from the SSC of the ISTH

4. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV

5. Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B – The MoHem study

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineering Synthetic and Recombinant Human Lysosomal b-Glucocerebrosidase for Enzyme Replacement Therapy for Gaucher Disease;2024-07-19

2. Correction;Expert Opinion on Biological Therapy;2024-04-02